Spinner,
In response to your prior question, the answer is that it simply does not matter in this case. GNBT is a holding company, not a doing company. They don't have to "do" anything. (Good thing they don't btw)...The companies underneath their umbrella are the worker bees and GNBT is the Queen in the hive.
As I see it, GNBT will continue to protect IP, protect the company legally and just keep "not doing" for the foreseeable future. The progress is from the owned-entities. That should be how a holding company works. It empowers the underlying entities to execute and focuses its own efforts towards larger-picture initiatives and offers a legal umbrella. This is also why we may hear more about lawsuits than business progress from the other companies.
Let's not hold the sins of the past (from a different business model) upon the current administration. They could have just decided to start a different company instead of bring GNBT back from the dead, but they did not and have had to deal with much of the issues from the past they have had to resolve. Now, all of the past issues seem to be resolved and they can finally move forward. This is what success for GNBT looks like for now...a near-silent company that cannot communicate with its investors as they have just submitted answers to a regulatory body for one of its subsidiaries. Within the next 30 days the FDA will respond with more questions that will require more activities, or with an approval of the IND package to move forward with human trials.
My hope is that the IPO for NGIO lists regardless of this approval, so that once approved, NGIO can gain the best increase that is possible from the news. In the latest interview with Joe, he indicated that NGIO would not have to do as many human trials as companies such as Pfizer, Modern and J&J vaccines due to NGIO using their already accepted formulas. I would like to know a range of the number per phase of trial that they need to vaccinate, so that we can have better expectations.
In my opinion, the question is not existential at all, it is a matter of timing and resource allocation. Hopefully the resources from their partnerships abroad are panning out, and it appears that when the USFDA provides approval of the IND, there will be yet another traunch of funding coming GNBT's direction. I seem to recall the number for that being somewhere around $50MM, but I cannot recall. Perhaps someone can provide some insight on that.
Regardless of partnerships abroad, there is strong potential for a universal booster in the domestic and developed world markets that NGIO can cash in upon with it being the only booster/vaccine combination in the market with the following attributes.
1. Room Temp Storage
2. Single-Shot Application
3. Long Term Memory
4. Safety Profile that is more widely accepted than mRNA/RNA
This grouping of attributes in my opinion is the "holy grail" to finally get all the fence-sitters who have yet to get the vaccine off of it and eradicate COVID-19 in developed countries.
I welcome questions and discussion on any of these points as we can all learn together.
Cheers!
In response to your prior question, the answer is that it simply does not matter in this case. GNBT is a holding company, not a doing company. They don't have to "do" anything. (Good thing they don't btw)...The companies underneath their umbrella are the worker bees and GNBT is the Queen in the hive.
As I see it, GNBT will continue to protect IP, protect the company legally and just keep "not doing" for the foreseeable future. The progress is from the owned-entities. That should be how a holding company works. It empowers the underlying entities to execute and focuses its own efforts towards larger-picture initiatives and offers a legal umbrella. This is also why we may hear more about lawsuits than business progress from the other companies.
Let's not hold the sins of the past (from a different business model) upon the current administration. They could have just decided to start a different company instead of bring GNBT back from the dead, but they did not and have had to deal with much of the issues from the past they have had to resolve. Now, all of the past issues seem to be resolved and they can finally move forward. This is what success for GNBT looks like for now...a near-silent company that cannot communicate with its investors as they have just submitted answers to a regulatory body for one of its subsidiaries. Within the next 30 days the FDA will respond with more questions that will require more activities, or with an approval of the IND package to move forward with human trials.
My hope is that the IPO for NGIO lists regardless of this approval, so that once approved, NGIO can gain the best increase that is possible from the news. In the latest interview with Joe, he indicated that NGIO would not have to do as many human trials as companies such as Pfizer, Modern and J&J vaccines due to NGIO using their already accepted formulas. I would like to know a range of the number per phase of trial that they need to vaccinate, so that we can have better expectations.
In my opinion, the question is not existential at all, it is a matter of timing and resource allocation. Hopefully the resources from their partnerships abroad are panning out, and it appears that when the USFDA provides approval of the IND, there will be yet another traunch of funding coming GNBT's direction. I seem to recall the number for that being somewhere around $50MM, but I cannot recall. Perhaps someone can provide some insight on that.
Regardless of partnerships abroad, there is strong potential for a universal booster in the domestic and developed world markets that NGIO can cash in upon with it being the only booster/vaccine combination in the market with the following attributes.
1. Room Temp Storage
2. Single-Shot Application
3. Long Term Memory
4. Safety Profile that is more widely accepted than mRNA/RNA
This grouping of attributes in my opinion is the "holy grail" to finally get all the fence-sitters who have yet to get the vaccine off of it and eradicate COVID-19 in developed countries.
I welcome questions and discussion on any of these points as we can all learn together.
Cheers!
8
